Transcatheter edge-to-edge repair offers interventional treatment option for symptomatic moderate-to-severe functional mitral regurgitation among patients with chronic heart failure, though randomized evidence demonstrates discordant results across landmark trials. Guideline-directed medical therapy optimization represents current standard preceding device consideration, creating uncertainty regarding net clinical benefit in contemporary optimized pharmacologic context. 
The study was published in the Eurointervention. Investigators conducted comprehensive meta-analysis of randomized trials comparing transcatheter edge-to-edge repair plus guideline-directed medical therapy versus guideline-directed medical therapy alone, systematically searching major electronic databases for eligible studies. Three pivotal randomized controlled trials—MITRA-FR, COAPT, and RESHAPE-HF2—provided individual patient-level data for 1,422 patients randomized to transcatheter edge-to-edge repair plus guideline-directed medical therapy (n=703) or guideline-directed medical therapy monotherapy (n=719). Primary outcome assessed composite of death or first heart failure hospitalization at 24 months, with key secondary endpoint capturing heart failure hospitalization alone. 
Primary Composite Endpoint Shows Treatment Benefit
One-stage analysis confirmed significant primary outcome reduction favoring transcatheter edge-to-edge repair plus guideline-directed medical therapy (hazard ratio 0.72, 95% confidence interval 0.56-0.92, P=0.010), reflecting 28% relative risk reduction in death or heart failure hospitalization at 24 months. Two-stage summary analysis demonstrated marginal statistical significance (hazard ratio 0.72, 95% confidence interval 0.51-1.00, P=0.052) but substantial heterogeneity across trials (I²=80.3%, P=0.006), underscoring patient selection variability.
Heart Failure Hospitalization Reduction Proves Robust
Heart failure hospitalization endpoint yielded consistent treatment benefit irrespective of statistical methodology: one-stage hazard ratio 0.65 (95% confidence interval 0.48-0.88, P=0.006) and two-stage hazard ratio 0.66 (95% confidence interval 0.45-0.96, P=0.031). Substantial heterogeneity persisted (I²=81.2%, P=0.005), reflecting differences in functional mitral regurgitation severity, left ventricular remodeling patterns, and guideline-directed medical therapy optimization levels across contributing studies.
Mortality Signals Emerge Through Sensitivity Analyses
All-cause and cardiovascular mortality demonstrated no significant between-group differences at 24 months within primary analysis, though leave-one-out sensitivity excluding MITRA-FR achieved statistical significance, suggesting trial-specific patient phenotypes influence survival trajectories.
Patient Selection Refinement Beyond Anatomic Severity
Interventional cardiologists and heart failure specialists gain synthesized evidence supporting transcatheter edge-to-edge repair integration into guideline-directed medical therapy-optimized functional mitral regurgitation management, particularly targeting recurrent hospitalization reduction. Heterogeneity underscores necessity for precise phenotyping incorporating pulmonary capillary wedge pressure, right ventricular-pulmonary artery coupling, and secondary tricuspid regurgitation burden alongside mitral anatomy.
Heart Team Implementation With Risk-Benefit Framework
Contemporary transcatheter edge-to-edge repair protocols should prioritize patients with disproportionate heart failure hospitalizations despite maximal tolerated guideline-directed medical therapy, leveraging 24-month heart failure risk reduction as primary decision criterion. Multicenter registries should prospectively validate meta-analytic findings while elucidating heterogeneity sources through core laboratory adjudication of functional mitral regurgitation mechanism, left ventricular geometry, and pulmonary hypertension profiles.